Prev Close | 6.52 |
Day Low/High | 6.03 / 6.45 |
52 Wk Low/High | 3.28 / 26.77 |
Prev Close | 6.52 |
Day Low/High | 6.03 / 6.45 |
52 Wk Low/High | 3.28 / 26.77 |
Exchange | NASDAQ |
Shares Outstanding | 63.01B |
Market Cap | 410.80M |
P/E Ratio | N/A |
Div & Yield | N.A. (N.A) |
Esperion Therapeutics, Agenus Inc. and Baudax Bio could see coming events trigger positive reactions in their shares.
Merger activity is the number 1 driver I am watching for biotech growth.
Strong markets tend to stay sticky to the upside, and the mild pressure on the indices isn't preventing some good stock picking.
There is much talk that IBM is overpaying for Red Hat, but this deal is a net positive for the market as a whole.
Biotech companies show more energy than the rest of the market Monday.
I'm starting a new periodic feature that will bring you the hottest-trading stocks I see.
Buyers were hesitant to keep pressing as the day wrapped up.
Not a big day of gains, but there is underlying support.
Gloom is gone as likelihood of Fed rate hike fades.
Wal-Mart sets the tone, but selling hasn't been bad enough to kill rally.
Oil- and commodity-related shares perform well.
Only one fund category (of 20) has beaten the S&P 500 over half a decade.
Thin volume likely ahead of holiday weekend.
A flood of supply in a nervous market isn't a good idea.
This sector could see some real damage.
Own them, or take something off the table?
Market backtracks on skepticism over biotechs.
For Bluebird Bio and Esperion, the charts tell the whole story.
A Fed-related dip may be your only hope to get in lower.
These companies are doing great -- take some profits!
A tale of two stocks with Esperion and DSW.
The chasing in certain areas was intense.
But stay disciplined, honor your stops and protect gains.
Three biotech companies are going public this week and NanoString looks better than Prosensa or Esperion says Francis Gaskins.